TA130 Rheumatoid arthritis - adalimumab and infliximab and TA186 Rheumatoid arthritis - certolizumab pegol: review proposal - November 2010
Proposal to combine and plan an update to the guidance into the appraisal work programme
The planned date for review of the above guidance was September 2010.
This is the date when the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake an update of the existing guidance.
The Institute has carried out a search for information relevant to these appraisals, and believes that it is appropriate for both pieces of existing guidance to be combined and updated. Golimumab should also be included within the update (expected publication date March 2011).
In order to be completely confident that this is appropriate, we are asking consultees and commentators with an interest in this topic, to inform us of any evidence which would suggest that an earlier review would be beneficial. We would particularly like to be made aware of timelines around on-going research, etc. which might affect the scheduling of this review should we go ahead with the proposal following this consultation.
Please see appendix A for a full list of the organisations we have contacted.
This page was last updated: 12 November 2010